Hi Jägermeister,
gerne habe ich mir deine IBEX angeschaut. Auch ich glaube an Biotech-Werte, aber ich denke, wir beide sind unserer Zeit ein wenig voraus. Der Kursverlauf der Aktie zeigt schwach in Richtung Süden, da konnten auch die guten News bisher nicht helfen. Aber ich denke schon, daß es sich mittelfristig lohnt dort einzusteigen. Gerade weil der Kurs unten steht.
Kurzinfo:
Ibex Technologies Inc. is a biopharmaceutical company developing enzymes for a variety of therapeutic applications such as cardiovascular disease, wound healing and diseases of genetic origin.
Weitere Infos siehe http://www.ibex.ca/
Pipeline
The Company`s pipeline flows primarily from its proprietary system flavobacterium heparinum, from which the Company can produce a number of enzymes of therapeutic interest, and from ORALASE its oral enzyme therapy technology.
Product
Candidate
Clinical
Application
Stage of
Development
NeutralaseTM
Cardiac Surgery
Angioplasty
LMWH Reversal
Vascular Surgery
Phase III
Phase II
Phase I
Phase I
ExtravaseTM
Reperfusion Injury
Restenosis
Chronic Wounds
Pre-clinical
Pre-clinical
Pre-clinical
PhenylaseTM
Phenylketonuria
Pre-clinical
IBT 9401
Anti-cancer
Pre-clinical
Neutralase™ (heparinase I): The Company`s lead product is Neutralase ™, which is being developed as a heparin neutralization agent. The Company`s objective is to show that Neutralase™ not only reverses the anticoagulant effects of heparin as well as the currently used drug, protamine, but that it has a number of significant advantages over protamine, notably, that unlike protamine, Neutralase™ does not cause hemodynamic perturbations.
In addition, Neutralase is expected to have advantages over protamine regarding preservation of platelet function, preservation of a portion of heparin`s anti-thrombotic activity, and reduced complement activation.
Cardiac Surgery
The most advanced indication for Neutralase is heparin neutralization following cardiac surgery. Heparin neutralization is required in over 400,000 bypass procedures annually in the United States and a further 250,000 in other countries. In August 1999, IBEX completed the first stage of a Phase III clinical trial. The interim analysis of this stage was judged by the Company to be positive, and warranted continuation of this trial. IBEX is currently seeking a corporate partner before restarting the trial.
Cardiology
IBEX is also evaluating the ability of Neutralase to speed up recovery and improve the outcome of patients undergoing coronary interventions in the cardiac catheterization laboratory.
Currently heparin is generally not reversed in this setting in part for fear of thrombotic and adverse cardiovascular responses which may result from the use of protamine. Using Neutralase, which retains some of heparin`s anti-Xa activity while eliminating its anticoagulant properties, patients may be protected from the thrombotic complications of coronary interventions while permitting earlier removal of vascular sheaths.
Antidote to New Class of Anticoagulants
Recent in-vitro studies demonstrate that Neutralase is the most effective agent in reversing the new class of anticoagulants which are now coming to market for a wide range of clinical uses. These experiments were presented by prominent researchers at the annual meeting of the American Society of Hematology held in New Orleans this past December.
Extravase™ (heparinase III): The Company is well advanced preclinically with its second product, Extravase, which is being developed to prevent the injury which occurs from reperfusion following ischemic events such as; heart attacks, stroke and organ transplantation. Extravase has also shown benefit in animal models of restenosis and wound healing.
Phenylase™: The Company is developing Phenylase™, an orally active drug for the treatment of phenylketonuria (PKU). The clinical objective of Phenylase is to replace the activity of phenylalanine hydroxylase the enzyme deficient in PKU. If effective, Phenylase will allow people suffering from PKU to eat a more normal diet.
Chondroitinase AC: The company is in preclinical development with Chondroitinase AC as an anti-cancer agent.
... und ich schör dir Stein und Bein, daß aber auch garnix davon verstehe
cu
CoolJazz